Scynexis Inc (SCYX)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $3.95
- As of
Kresmion compiles this page from SCYX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
SCYNEXIS INC (SCYX): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-28.
See the full SCYX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SCYX on one page. Preview it with sample data, then open it live with a free account.
Preview the SCYX dossierActive events for SCYX
- mediumEarnings above estimates
Q2-2026: Beat consensus by 221.9%, EPS $0.63 vs $-0.5168 estimate
- medium13F: new position
RENAISSANCE TECHNOLOGIES LLC new position in SCYX
- medium13F: new position
MILLENNIUM MANAGEMENT LLC new position in SCYX
- mediumEarnings above estimates
Q2-2025: Beat consensus by 27.8% - EPS $-1.12 vs $-1.5504 estimate
- mediumEarnings above estimates
Q3-2025: Beat consensus by 16.7% - EPS $-1.36 vs $-1.632 estimate
FREE, NO ACCOUNT
Every event on SCYX, as it fires
You are seeing 5 of 13 events recorded on SCYX since 2026-06-01.
The five above landed across 4 days. The other 8 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SCYX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 811292309 · 2026Q2 | $736K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 811292309 · 2026Q2 | $311K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SCYX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
SCYX against its peers
SCYX's operating margin of -78.0% ranks in the 23rd percentile of 14 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | SCYX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 20.6M USD | 35.2M USD | 38 | 16 |
| Gross margin | n/a | 43.5% | n/a | 13 |
| Operating margin | -78.0% | -12.6% | 23 | 14 |
| Net margin | -41.8% | -21.8% | 38 | 16 |
| Return on equity | -17.4% | -26.3% | 57 | 14 |
Peers (19): IXHL, CXXIF, RAPH, LEEEF, PLNH, RMTI, CPHI, ETST, TLPH, ITHUF, INIS, SHPH, CPIX, MRMD, BIOE, AYTU, TXMD, CWBHF, ZYBT. Left out: CYPA (no annual filing), MCUJF (period gap), HSTI (period gap), CPIVF (no annual filing), CTOR (no annual filing), INCR (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (SCYX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow SCYX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to SCYX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.